Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics Inc (VYGR) is a leader in developing gene therapies for central nervous system disorders through its proprietary TRACER™ platform. This page provides investors and researchers with essential updates on clinical developments, strategic partnerships, and scientific breakthroughs in AAV-based treatments.
Access curated press releases and news articles covering key milestones in Voyager’s pipeline, including therapies for Parkinson’s disease, ALS, and Friedreich’s ataxia. Stay informed about advancements in blood-brain barrier penetration technology and preclinical validation studies across multiple species.
Our repository features updates on clinical trial progress, regulatory developments, and collaborative research initiatives. Discover analysis of vector optimization achievements and manufacturing scalability efforts critical to gene therapy commercialization.
Bookmark this page for consolidated access to verified information about Voyager’s neurogenetic innovations. Check regularly for objective reporting on therapeutic candidate progression and industry leadership in CNS-targeted gene delivery solutions.
Rhea-AI Summary
Voyager Therapeutics, Inc. reported strong financial results for Q4 2023 and full year 2023, with approximately $431 million in pro-forma cash as of December 31, 2023. The company achieved key milestones, including strategic collaborations with Novartis and Neurocrine Biosciences. Voyager expects to advance multiple programs into the clinic by the end of next year, with a focus on gene therapy programs for diseases like Alzheimer's and ALS. The company's cash position and anticipated milestones provide runway into 2027, supporting the generation of clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.25%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. announces the selection of a lead development candidate in the Friedreich’s ataxia program in collaboration with Neurocrine Biosciences. The candidate combines a frataxin gene replacement payload with a novel capsid derived from Voyager’s TRACER platform. The program is expected to enter first-in-human clinical trials in 2025, triggering a $5 million milestone payment to Voyager. Voyager could receive additional milestone payments based on program advancement. The strategic collaboration aims to address the challenging FA disease through gene therapy, with potential milestone payments of up to $1.3 billion for Voyager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will report Q4 2023 financial results on Feb 28, 2024. A conference call and webcast will follow to review the results. Participants can register in advance to join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced new data on VY-TAU01, their lead anti-tau antibody, and tau silencing gene therapy program for Alzheimer's disease treatment. The data, to be presented at AD/PD™ 2024, show promising results in non-human primates and mice. Voyager plans to file an IND for VY-TAU01 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. will present at the Oppenheimer Life Sciences Conference on February 14, 2024. The webcast of the presentation can be accessed from the Investors section of Voyager's website. Chief Financial Officer Peter Pfreundschuh will be presenting at 11:20 a.m. ET. A replay of the webcast will be available on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant, for aggregate gross proceeds of approximately $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a public offering of $100 million of shares of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares. The net proceeds will be used for advancing its neurogenetic medicines and various clinical and preclinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference. The webcast can be accessed from the Investors section of Voyager’s website, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.67%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will receive $100 million up-front and is eligible for up to $1.2 billion in milestone payments and tiered royalties. Novartis will pay Voyager $100 million, including a $20 million purchase of newly issued equity, and is eligible to receive milestone payments and tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced the selection of a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The company anticipates filing an investigational new drug (IND) application with the FDA for the candidate in mid-2025. The candidate has shown a 73% reduction of SOD1 in cervical spinal cord motor neurons in a non-human primate study, with an ability to transduce both neurons and astrocytes. Data previously shared at the 2022 ASGCT annual meeting demonstrated an increase in survival by a median of 152 days in a G93A mouse model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
Voyager Therapeutics Inc
Nasdaq:VYGR
VYGR Rankings
VYGR Stock Data
174.45M
46.01M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON